Skip To The Main Content

This provides a unique opportunity for our patients who have certain challenging diagnoses to help test the latest drugs and be a part of the search for more effective procedures.

Current clinical trials include:

Lung Cancer

  • ECOG1505

A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)

View Clinical Trial

Breast Cancer

  • NSABP 39/RTOG 0143

A Randomized Phase III Study of Conventional Whole Breast Irradiation( WBI) Versus Partial Breast Irradiation( PBI) for Women with Stage 0, I or II Breast Cancer

View Clinical Trial

  • NSABP 40

A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with
Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens

View Clinical Trial

  • NSABP 38

A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens 
in Women with Node-positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC®P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC®PG)

View Clinical Trial

  • NSABP 35

A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy

View Clinical Trial

  • SWOG 0307

Phase III Trial of Biphosphonates as Adjuvant Therapy for Primary Breast Cancer

View Clinical Trial

  • ECOG 5103

 A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

View Clinical Trial

  • PROMIS

PRospective study Of MammaPrint in breast cancer patients with an Intermediate recurrence Score (PROMIS).”

View Clinical Trial


Hepatitis C

1220.47

A Phase III, Randomized, Double Blind and Placebo Controlled Study of Once Daily BI 201335 120 mg for 24 Weeks and BI 201335 240 mg for 12 Weeks in Combination With Pegylated Interferon Alpha and Ribavirin in Treatment Naive Patients With Genotype 1 Chronic Hepatitis C Infection.

View Clinical Trial

1220.48

A Phase III, Open-label Study of Once Daily BI 201335 240 mg for 24 Weeks in Combination With Pegylated interferon-a (PegIFN) and Ribavirin (RBV) in Patients With Genotype 1 Chronic Hepatitis C Infection Who Failed a Prior PegIFN / RBV Treatment

View Clinical Trial

1220.7

A Phase III, Randomized, Double-blind and Placebo Controlled Study of Once Daily BI 201335, 240 mg for 12 or 24 Weeks in Combination With Pegylated interferon-a (PegIFNa) and Ribavirin (RBV) in Patients With Genotype 1 Chronic Hepatitis C Infection Who Failed a Prior PegIFN/RBV Treatment

View Clinical Trial

Roche NV27779

A Phase II, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Sutained Virlologic Response of the HCV Polymerase Inhibitor Prodrug RO5024048 in Combination with Telaprevir and Pegasys/Copegus compared with Telaprevir and Pegasys/Copegus

View Clinical Trial

Human Immunodeficiency Virus HIV

GS-US-292-0104

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

View Clinical Trial

Clostridium difficile

H030014

Efficacy, Immunogenicity, and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection

View Clinical Trial

Vaccine Website: http://www.cdiffense.org/home

Neurology

A Multinational, Multi-Center, Randomized Double-Blind, Placebo Controlled,  Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 weeks in Patients with Chronic Peripheral Neuropathic pain.

View Clinical Trial

Cardiology

LTS11717

Long term safety and tolerability of REGN727/SAR236553 in high cardiovascular risk patients with hypercholesterolemia not adequately controlled with their lipid modifying therapy: a randomized, double- blind placebo-controlled study.

View Clinical Trial

EFC 11570

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

View Clinical Trial

CCSF 2011-001

A randomized, double-blind placebo-controlled study of the short-term clinical effects of Tolvaptan in patients hospitalized for worsening heart failure with challenging volume management.

View Clinical Trial

DAP RENSE 08-05

A Prospective, Multicenter, Randomized Evaluator-Blinded Comparator-Controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections(cSSSI) and Staphlococcus Aureus Bacteremia among Subjects of Moderate or Severe Renal Impairment

View Clinical Trial

EFDFU003

A Prospective, Randomized, Comparative Parallel Study of Amniotic Membrane Wound Graft in Management of Diabetic Foot Ulcers.

View Clinical Trial

EPIFIX-001

A Multi-center Randomized Controlled Clinical Trial Evaluating Two Application Regimens of EpiFix® Dehydrated Human Amniotic Membrane and Standard of Care vs. Standard of Care Alone in the Treatment of Venous Leg Ulcers.

View Clinical Trial

Podimetrics

In-Home Assessment of a Smart Foot Mat for Prevention of Diabetic Foot Ulcers

Other resources for clinical trial information:

www.clinicaltrials.gov

www.centerwatch.com

www.nih.gov

mammogram

MetroWest Medical Center provides advanced medicine and personalized care, right here in your community.

Learn More

vip-program

Become a VIP (Very Important Patient) and get free access to a trained Personal Health Guide.

Learn More

heartvascular

The Center for Heart & Vascular Services. At the forefront of heart and vascular disease for more than 25 years.

Learn More